DEANNA STOPPERICH: Open Payments
NPI 1902076284 · JAMESTOWN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,392 in 91 payments from 14 companies in 2025. Trend: 2023 $1,270 · 2024 $1,666 · 2025 $1,392
Food & beverage: $1,392
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $275 |
| Lilly USA, LLC | 14 | $224 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $223 |
| Amgen Inc. | 11 | $193 |
| GlaxoSmithKline, LLC. | 9 | $135 |
| AstraZeneca Pharmaceuticals LP | 4 | $70 |
| Astellas Pharma US Inc | 2 | $65 |
| Lundbeck LLC | 3 | $53 |
| Endo USA, Inc. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
Products named: CAPLYTA, MOUNJARO, TRELEGY ELLIPTA, VRAYLAR, OTEZLA, REXULTI, UBRELVY, EVENITY.
Industry payments across IN — which companies pay providers there.
